OCMS Bio is a Monoclonal Antibody Discovery Tools Company. Our proprietary technology On-Cell mAb Screening (OCMS pronounced as in "Occam's razor"), greatly speeds antibody discovery. OCMS fluorescent imaging methods transform mAb discovery from patient-derived antibodies, transgenic mouse models, and Artificial Intelligence (AI) antibody engineering. A major focus of our internal research program is AI-driven pandemic prevention.
LEARN MORE
OCMS Bio provides discovery and engineering tools and services for the monoclonal antibody and related industries. Its proprietary On Cell mAb Screening technology allows it to evaluate millions of antibodies expressed in mammalian cells, at a fraction of the time and cost of traditional methods. By delivering data on binding and expression levels for every antibody screened, OCMS enables its partners to discover and optimize “one in a million” antibodies.
LEARN MORE
Accelerating AI-Based Antibody Discovery & Engineering